Drug Trial Radar · NCT00631371
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Last checked: Nov 20, 2026Latest source record: Apr 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
791
Actual
Start
Apr 2008
Primary completion
Apr 2012
Study completion Apr 2015
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.
Conditions
- Renal Cell Carcinoma
Interventions
BevacizumabDrug
Bevacizumab 10 mg/kg intravenous (IV) q8wks
TemsirolimusDrug
Temsirolimus 25 mg IV weekly
BevacizumabDrug
Bevacizumab 10 mg/kg intravenous (IV) q8wks
Interferon-Alfa 9MUDrug
Interferon-Alfa 9MU SC TIW
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS): Independent-AssessmentTime frame: Baseline until disease progression, initiation of new anticancer treatment, or death, assessed every 8 weeks (up to cut-off date: 19 April 2012)
Locations
172 sites in 30 countries. Site status is shown where the registry gives one.
Hematology Oncology Services of Arkansas
Little Rock, Arkansas
South County Hematology/Oncology
Chula Vista, California
Cancer Center Oncology Medical Group
La Mesa, California
UCLA Medical Center
Los Angeles, California
UCLA
Los Angeles, California
UCLA
Los Angeles, California
North County Oncology Medical Clinic
Oceanside, California
Medical Oncology Associates - SD
San Diego, California
Sharp Memorial Hospital Investigational Pharmacy
San Diego, California
Sharp Rees-Stealy
San Diego, California
California Pacific Medical Center
San Francisco, California
Pacific Hematology/Oncology Associates
San Francisco, California
San Francisco Oncology Associates
San Francisco, California
Cohen & Hufford MD's INC
San Francisco, California
The Jones Clinic, PC
New Albany, Mississippi
The Cleveland Clinic
Cleveland, Ohio
Edmond Oncology Center
Edmond, Oklahoma
OU Medical Center
Oklahoma City, Oklahoma
OU Physician's Building
Oklahoma City, Oklahoma
University of Oklahoma
Oklahoma City, Oklahoma
The Jones Clinic, PC
Germantown, Tennessee
The Vanderbilt Clinic
Nashville, Tennessee
University of Washington Medical Center
Seattle, Washington
Virginia Mason Medical Center
Seattle, Washington
Seattle Cancer Care Alliance
Seattle, Washington
Centro Oncológico Rosario
Rosario, Santa Fe Province, Argentina
ISIS Clinica Especializado
Santa Fe, Santa Fe Province, Argentina
Centro Medico San Roque
San Miguel de Tucumán, Tucumán Province, Argentina
Cancer Care SA
Kurralta Park, Australia
Mater Private Hospital
South Brisbane, Australia
Mater Adult Hospital
South Brisbane, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Ashford Cancer Center Research
Kurralta Park, South Australia, Australia
ZNA Middelheim
Antwerp, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Jessa Ziekenhuis - campus Virga Jessa
Hasselt, Belgium
Cliniques Universitaires de Mont-Godinne UCL
Mont-Godinne, Belgium
Irmandade da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Brazil
Centro Goiano de Oncologia
Goiânia, Goiás, Brazil
Centro Goiano de Oncologia - CGO
Goiânia, Goiás, Brazil
Showing 40 of 172 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.